Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers
Background: In the first-line treatment of biliary tract cancers (BTCs), XELOX (capecitabine plus oxaliplatin) showed comparable clinical efficacy and safety to gemcitabine and oxaliplatin (GEMOX), with fewer visits and better treatment management. Our study aims to investigate the cost-effectivenes...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.871262/full |
| _version_ | 1811289077545172992 |
|---|---|
| author | Ruijia Chen Yalan Zhang Kongying Lin Defu Huang MaoJin You Yanjin Lai Jinye Wang Yingying Hu Na Li Na Li |
| author_facet | Ruijia Chen Yalan Zhang Kongying Lin Defu Huang MaoJin You Yanjin Lai Jinye Wang Yingying Hu Na Li Na Li |
| author_sort | Ruijia Chen |
| collection | DOAJ |
| description | Background: In the first-line treatment of biliary tract cancers (BTCs), XELOX (capecitabine plus oxaliplatin) showed comparable clinical efficacy and safety to gemcitabine and oxaliplatin (GEMOX), with fewer visits and better treatment management. Our study aims to investigate the cost-effectiveness of XELOX and GEMOX as the first-line therapy for BTCs from the perspective of the Chinese healthcare systems and to provide valuable suggestions for clinical decision-making.Methods: A Markov model was developed using the phase 3 randomized clinical trial (ClinicalTrials.gov number, NCT01470443) to evaluate the cost-effectiveness of XELOX and GEMOX. Quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) were used as the primary outcomes of the model. Uncertainty was assessed using univariate and probabilistic sensitivity analysis.Results: The QALYs for the XELOX and GEMOX groups were 0.66 and 0.54, respectively. In China, the total cost of XELOX treatment is US $12,275.51, which is lower than that of the GEMOX regimen. In addition, XELOX is more effective than GEMOX, making it the preferred regimen. A sensitivity analysis determined that XELOX therapy has a stable economic advantage in China.Conclusion: Compared to GEMOX, XELOX is a more cost-effective treatment as a first-line treatment for advanced BTC from the perspective of the Chinese health service system. |
| first_indexed | 2024-04-13T03:48:36Z |
| format | Article |
| id | doaj.art-034534081078427eb1a6aa2d29b11c65 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-13T03:48:36Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-034534081078427eb1a6aa2d29b11c652022-12-22T03:03:53ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-07-011310.3389/fphar.2022.871262871262Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract CancersRuijia Chen0Yalan Zhang1Kongying Lin2Defu Huang3MaoJin You4Yanjin Lai5Jinye Wang6Yingying Hu7Na Li8Na Li9Department of Pharmacy, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, ChinaDepartment of Pharmacy, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, ChinaDepartment of Hepatopancreatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, ChinaDepartment of Pharmacy, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, ChinaDepartment of Pharmacy, Mindong Hospital of Fujian Medical University, Ningde, ChinaDepartment of Pharmacy, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, ChinaDepartment of Pharmacy, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, ChinaDepartment of Pharmacy, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, ChinaDepartment of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, ChinaThe School of Pharmacy, Fujian Medical University, Fuzhou, ChinaBackground: In the first-line treatment of biliary tract cancers (BTCs), XELOX (capecitabine plus oxaliplatin) showed comparable clinical efficacy and safety to gemcitabine and oxaliplatin (GEMOX), with fewer visits and better treatment management. Our study aims to investigate the cost-effectiveness of XELOX and GEMOX as the first-line therapy for BTCs from the perspective of the Chinese healthcare systems and to provide valuable suggestions for clinical decision-making.Methods: A Markov model was developed using the phase 3 randomized clinical trial (ClinicalTrials.gov number, NCT01470443) to evaluate the cost-effectiveness of XELOX and GEMOX. Quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) were used as the primary outcomes of the model. Uncertainty was assessed using univariate and probabilistic sensitivity analysis.Results: The QALYs for the XELOX and GEMOX groups were 0.66 and 0.54, respectively. In China, the total cost of XELOX treatment is US $12,275.51, which is lower than that of the GEMOX regimen. In addition, XELOX is more effective than GEMOX, making it the preferred regimen. A sensitivity analysis determined that XELOX therapy has a stable economic advantage in China.Conclusion: Compared to GEMOX, XELOX is a more cost-effective treatment as a first-line treatment for advanced BTC from the perspective of the Chinese health service system.https://www.frontiersin.org/articles/10.3389/fphar.2022.871262/fullcost-effectivenessadvanced biliary tract cancersXELOXGEMOXfirst-line treatment |
| spellingShingle | Ruijia Chen Yalan Zhang Kongying Lin Defu Huang MaoJin You Yanjin Lai Jinye Wang Yingying Hu Na Li Na Li Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers Frontiers in Pharmacology cost-effectiveness advanced biliary tract cancers XELOX GEMOX first-line treatment |
| title | Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers |
| title_full | Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers |
| title_fullStr | Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers |
| title_full_unstemmed | Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers |
| title_short | Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers |
| title_sort | cost effectiveness analysis of capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first line therapy for advanced biliary tract cancers |
| topic | cost-effectiveness advanced biliary tract cancers XELOX GEMOX first-line treatment |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.871262/full |
| work_keys_str_mv | AT ruijiachen costeffectivenessanalysisofcapecitabineplusoxaliplatinversusgemcitabineplusoxaliplatinasfirstlinetherapyforadvancedbiliarytractcancers AT yalanzhang costeffectivenessanalysisofcapecitabineplusoxaliplatinversusgemcitabineplusoxaliplatinasfirstlinetherapyforadvancedbiliarytractcancers AT kongyinglin costeffectivenessanalysisofcapecitabineplusoxaliplatinversusgemcitabineplusoxaliplatinasfirstlinetherapyforadvancedbiliarytractcancers AT defuhuang costeffectivenessanalysisofcapecitabineplusoxaliplatinversusgemcitabineplusoxaliplatinasfirstlinetherapyforadvancedbiliarytractcancers AT maojinyou costeffectivenessanalysisofcapecitabineplusoxaliplatinversusgemcitabineplusoxaliplatinasfirstlinetherapyforadvancedbiliarytractcancers AT yanjinlai costeffectivenessanalysisofcapecitabineplusoxaliplatinversusgemcitabineplusoxaliplatinasfirstlinetherapyforadvancedbiliarytractcancers AT jinyewang costeffectivenessanalysisofcapecitabineplusoxaliplatinversusgemcitabineplusoxaliplatinasfirstlinetherapyforadvancedbiliarytractcancers AT yingyinghu costeffectivenessanalysisofcapecitabineplusoxaliplatinversusgemcitabineplusoxaliplatinasfirstlinetherapyforadvancedbiliarytractcancers AT nali costeffectivenessanalysisofcapecitabineplusoxaliplatinversusgemcitabineplusoxaliplatinasfirstlinetherapyforadvancedbiliarytractcancers AT nali costeffectivenessanalysisofcapecitabineplusoxaliplatinversusgemcitabineplusoxaliplatinasfirstlinetherapyforadvancedbiliarytractcancers |